Drug Type Fusion protein |
Synonyms |
Target |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors), TGF-β3 inhibitors(Transforming growth factor beta 3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mycosis Fungoides | Phase 1 | US | 15 Feb 2019 | |
Malignant Solid Neoplasm | Phase 1 | US | 07 Jan 2019 | |
Malignant Solid Neoplasm | Phase 1 | CA | 07 Jan 2019 | |
Metastatic Solid Tumor | Phase 1 | CA | 07 Jan 2019 | |
Metastatic Solid Tumor | Phase 1 | US | 07 Jan 2019 | |
Solid tumor | Phase 1 | CA | 07 Jan 2019 | |
Solid tumor | Phase 1 | US | 07 Jan 2019 | |
Scleroderma, Diffuse | Phase 1 | US | 01 Jan 2019 | |
Primary Myelofibrosis | Phase 1 | - | - | |
Scleroderma, Systemic | Phase 1 | - | - |
NCT03831438 (EULAR2020) Manual | Phase 1 | - | (jjiyfuztuw) = single cases of Grade 1 dizziness and CPK elevation, and Grade 2 anemia hyydybrtgd (thpqepgtwq ) | Positive | 04 Jun 2020 |